Actelion Company Profile (OTCMKTS:ALIOF)

About Actelion

Actelion logoActelion Ltd is a Switzerland-based biopharmaceutical company that focuses on the discovery, development and commercialization of drugs for diseases with unmet medical needs. The Company specializes in the field of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. Its portfolio of PAH treatments includes Opsumit (macitentan), Tracleer (bosentan), Uptravi (selexipag), Veletri (epoprostenol for injection) and Ventavis (iloprost). Opsumit is an orally available endothelin receptor antagonist (ERA). Tracleer is an orally available endothelin receptor antagonist (ERA). Uptravi is an oral, selective IP receptor agonist targeting the prostacyclin pathway in PAH. Veletri (epoprostenol for injection) is an intravenous prostacyclin. Ventavis is an inhaled formulation of iloprost, a synthetic compound similar to prostacyclin (PGI2).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: ALIOF
  • CUSIP:
Key Metrics:
  • Previous Close: $268.06
  • 50 Day Moving Average: $250.33
  • 200 Day Moving Average: $192.85
  • 52-Week Range: $103,107,000.00 - $138.01
  • Trailing P/E Ratio: 41.59
  • Foreward P/E Ratio: 30.67
  • P/E Growth: 3.12
  • Market Cap: $27.64B
  • Outstanding Shares: 103,107,000
  • Beta: 1.43
  • Net Margins: 29.59%
  • Return on Equity: 55.05%
  • Return on Assets: 37.46%
  • Current Ratio: 2.15%
  • Quick Ratio: 1.91%
Additional Links:
Companies Related to Actelion:

Analyst Ratings

Consensus Ratings for Actelion (OTCMKTS:ALIOF) (?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for Actelion (OTCMKTS:ALIOF)
DateFirmActionRatingPrice TargetDetails
1/5/2017Jefferies Group LLCDowngradeBuy -> HoldView Rating Details
6/25/2015HSBC Holdings plcInitiated CoverageHoldView Rating Details
(Data available from 2/26/2015 forward)


Earnings History for Actelion (OTCMKTS:ALIOF)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/20/2015$1.61$1.90ViewN/AView Earnings Details
4/21/2015$1.28$1.68ViewN/AView Earnings Details
2/16/2015$1.13$0.81ViewN/AView Earnings Details
10/21/2014$1.50$1.61ViewN/AView Earnings Details
7/23/2014$1.37$2.00ViewN/AView Earnings Details
4/21/2014$1.12$1.65ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Actelion (OTCMKTS:ALIOF)
Current Year EPS Consensus Estimate: $7.58 EPS
Next Year EPS Consensus Estimate: $8.74 EPS


Dividend History for Actelion (OTCMKTS:ALIOF)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Actelion (OTCMKTS:ALIOF)
No insider trades for this company have been tracked by


Latest Headlines for Actelion (OTCMKTS:ALIOF)
DateHeadline logoUnited Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss (OTCMKTS:ALIOF) - February 23 at 3:28 PM logoActelion Ltd. :ALIOF-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017 (OTCMKTS:ALIOF) - February 16 at 3:32 PM logoActelion Ltd. :ALIOF-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017 (OTCMKTS:ALIOF) - February 16 at 8:07 AM logoActelion FY16 Profit Rises (OTCMKTS:ALIOF) - February 14 at 1:56 AM logoJust 2 of the 13 Largest Drugmakers Have More Cash Than Debt -- Can You Guess Who They Are? (OTCMKTS:ALIOF) - February 8 at 3:37 PM logoJohnson & Johnson May Never Recoup Its Costs to Buy Actelion (OTCMKTS:ALIOF) - February 4 at 1:41 AM logoJ&J to Acquire Actelion for $30B: Is It a Strategic Fit? (OTCMKTS:ALIOF) - January 27 at 3:35 PM
News IconGlobal Stock Index On Verge Of All-Time High Propelled By "Dow 20,000" Euphoria (OTCMKTS:ALIOF) - January 27 at 1:47 AM
News IconJohnson & Johnson Acquires European Biotech Giant Actelion For $30 Billion (OTCMKTS:ALIOF) - January 26 at 8:45 PM logoJohnson & Johnson To Buy Actelion For $30 Bln With Spin-out Of New R&D Company (OTCMKTS:ALIOF) - January 26 at 8:45 PM logoActelion Stock Up On $30 Bln Takeover Deal With JNJ; To Spin-Out R&D To New Firm (OTCMKTS:ALIOF) - January 26 at 8:45 PM logo[$$] J&J/Actelion: high pressure sale (OTCMKTS:ALIOF) - January 26 at 3:43 PM logo[$$] Johnson & Johnson to buy Swiss biotech company Actelion for $30bn (OTCMKTS:ALIOF) - January 26 at 3:43 PM logo[$$] J&J digs deep to claim its $30bn Actelion prize (OTCMKTS:ALIOF) - January 26 at 3:43 PM logoJohnson & Johnson (JNJ) Stock Could Win BIG After Actelion Purchase (OTCMKTS:ALIOF) - January 26 at 12:15 PM logoActelion Founder's $1.5 Billion Payday Gives Him Shot at More - Bloomberg (OTCMKTS:ALIOF) - January 26 at 12:11 PM logoEurope Markets: European stocks hang at 1-year high, buoyed by Actelion and bank shares (OTCMKTS:ALIOF) - January 26 at 6:05 AM logoJ&J Seals $30 Billion Actelion Deal to Enter Rare Disease Arena - Bloomberg (OTCMKTS:ALIOF) - January 26 at 4:39 AM logo[$$] Novartis: buying time (OTCMKTS:ALIOF) - January 25 at 3:32 PM logoJohnson & Johnson CEO Talks Trump, Taxes and M&A After Mixed Earnings (OTCMKTS:ALIOF) - January 24 at 8:49 PM logoJ&J (JNJ) Q4 Earnings Top; Seeks Options for Diabetes Unit (OTCMKTS:ALIOF) - January 24 at 3:48 PM logo[$$] J&J disappoints on 2017 forecasts due to strong dollar (OTCMKTS:ALIOF) - January 24 at 3:48 PM logoJohnson & Johnson CEO Talks Trump, M&A After Mixed Earnings (OTCMKTS:ALIOF) - January 24 at 3:48 PM logo5 Best Performing Healthcare Mutual Funds of 2016 (OTCMKTS:ALIOF) - January 23 at 3:29 PM logoVIVUS Licenses Rights to PAH Drugs from Selten Pharma (OTCMKTS:ALIOF) - January 11 at 3:45 PM logo4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal (OTCMKTS:ALIOF) - January 10 at 3:29 PM logoUnited Therapeutics' PAH Suite Bodes Well, Competition Rife (OTCMKTS:ALIOF) - December 29 at 3:29 PM logoJ&J Resumes Talks with Actelion: Did Sanofi Just Lose Out? (OTCMKTS:ALIOF) - December 22 at 3:26 PM logo[$$] Actelion/J&J: hypertension tactics (OTCMKTS:ALIOF) - December 22 at 3:26 PM logoWall Street's M&A Chatter From December 21 (OTCMKTS:ALIOF) - December 22 at 7:27 AM logoActelion and Johnson & Johnson enter into exclusive discussions (OTCMKTS:ALIOF) - December 21 at 4:28 PM logo[$$] Johnson & Johnson and Actelion disclose 'exclusive' deal talks (OTCMKTS:ALIOF) - December 21 at 4:28 PM logoEuropean Stocks Drift Lower; Dollar Dominates Global Financial Markets (OTCMKTS:ALIOF) - December 16 at 3:33 PM logo5 Things You Must Know Before the Market Opens Friday (OTCMKTS:ALIOF) - December 16 at 3:33 PM logoActelion receives positive CHMP opinion for chlormethine gel (Ledaga) for the treatment of MF-CTCL (OTCMKTS:ALIOF) - December 16 at 3:33 PM logoJohnson & Johnson Looks for New Deal That's Just Right (OTCMKTS:ALIOF) - December 15 at 3:52 PM logoActelion's Independent Streak Gives Rise to Doubt That Sanofi Will Fill the Breach (OTCMKTS:ALIOF) - December 14 at 8:43 PM logo[$$] Actelion: PAH, humbug (OTCMKTS:ALIOF) - December 14 at 8:43 PM logoJ&J (JNJ) Ends Deal Talks with Actelion: Will Sanofi Gain? (OTCMKTS:ALIOF) - December 14 at 3:39 PM logo[$$] Sanofi in talks to acquire biotech Actelion as J&J bows out (OTCMKTS:ALIOF) - December 14 at 1:31 AM
News IconJohnson & Johnson approaches Actelion about takeover deal (OTCMKTS:ALIOF) - December 8 at 3:38 PM logoActelion Is a Perfect Fit for Sanofi, but Probably Too Expensive: Exane BNP (OTCMKTS:ALIOF) - December 7 at 4:06 PM logoSanofi SA (ADR) (SNY) Could Challenge Johnson & Johnson (JNJ) Bid For Actelion Ltd (ALIOF) (OTCMKTS:ALIOF) - December 6 at 12:48 PM logoActelion : J&J is raising offer for Actelion - source (OTCMKTS:ALIOF) - November 30 at 12:41 PM logoJohnson & Johnson Throws Caution to the Wind With a Large Bid for Actelion (OTCMKTS:ALIOF) - November 30 at 12:41 PM logoActelion Ltd. breached its 50 day moving average in a Bullish Manner : ALIOF-US : November 28, 2016 (OTCMKTS:ALIOF) - November 29 at 1:25 PM logoJ&J (JNJ) Confirms it Approached Actelion for Possible Deal (OTCMKTS:ALIOF) - November 29 at 1:25 PM logoStock Market News for November 28, 2016 (OTCMKTS:ALIOF) - November 29 at 1:25 PM logo[$$] Actelion: independent thinking (OTCMKTS:ALIOF) - November 29 at 1:25 PM logo[$$] Actelion weighs complicated deal to combine with part of J&J (OTCMKTS:ALIOF) - November 29 at 1:25 PM


What is Actelion's stock symbol?

Actelion trades on the OTCMKTS under the ticker symbol "ALIOF."

How do I buy Actelion stock?

Shares of Actelion can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Actelion stock cost?

One share of Actelion stock can currently be purchased for approximately $268.06.

Actelion (OTCMKTS:ALIOF) Chart for Sunday, February, 26, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Actelion (OTCMKTS:ALIOF)

Earnings History Chart

Earnings by Quarter for Actelion (OTCMKTS:ALIOF)

Dividend History Chart

Dividend Payments by Quarter for Actelion (OTCMKTS:ALIOF)

Last Updated on 2/26/2017 by Staff